Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 17/20 | 1.00 |
| ▸ | CYSLTR1 | Q9Y271 | 17/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709328 | 1.00 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1KDM4ENPC1LMNA | |
| SCHEMBL10402303 | 0.87 | CYSLTR2 (0.77) | CYSLTR2CYSLTR1PPARA | |
| SCHEMBL711192 | 0.87 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1 | |
| SCHEMBL711191 | 0.87 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1 | |
| SCHEMBL10402305 | 0.87 | CYSLTR2 (0.77) | CYSLTR2CYSLTR1PPARA | |
| SCHEMBL10402523 | 0.80 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1KDM4ENPC1LMNA | |
| SCHEMBL10402525 | 0.80 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1KDM4ENPC1LMNA | |
| SCHEMBL10402473 | 0.80 | CYSLTR1 (0.66) | CYSLTR2CYSLTR1 | |
| SCHEMBL10402471 | 0.80 | CYSLTR1 (0.66) | CYSLTR2CYSLTR1 | |
| SCHEMBL10402469 | 0.80 | CYSLTR1 (0.66) | CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124625-B2 | enhancing the expression of apoAI; prevention or therapy of dislipidemia | SHIONOGI & CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8053445-B2 | Utilities of olefin derivatives | SHIONOGI & CO., LTD. (JP) | 2011-11-08 | — | — | US | disclosed |
| US-20090036457-A1 | Utilities of olefin derivatives | YAMAMORI TERUO | 2009-02-05 | — | — | US | disclosed |
| US-20040242615-A1 | Utilities of olefin derivatives | SHIONOGI & CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242615-A1 | Utilities of olefin derivatives | APOL1, NR1H2, APOB | CYSLTR2 1193/4885CYSLTR1 1477/4885KDM4E 4415/4885 |
| US-20090036457-A1 | Utilities of olefin derivatives | APOL1, APOB, NR1H2 | CYSLTR2 1385/4885CYSLTR1 1771/4885KDM4E 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.